Ayal Hendel

Bar-Ilan University — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index4.2kcitations63works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(37), Virus-based gene therapy research(12), DNA Repair Mechanisms(9), RNA Interference and Gene Delivery(7), Immunodeficiency and Autoimmune Disorders(7)

Publications63 total

Gene-corrected regulatory T cell therapy for IL2RA deficiency
Molecular Therapy·2025· 1 cited
Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma
Blood·2025Open Access
Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)
Frontiers in Genome Editing·2025Open Access
247 UCCT-BCMA-1: a first-in-human, non-viral CRISPR-engineered CAR T cell therapy targeting BCMA in relapsed/refractory multiple myeloma
Regular and Young Investigator Award Abstracts·2025Open Access
Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
Molecular Therapy — Nucleic Acids·2025· 29 citedOpen Access
Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years
Frontiers in Immunology·2025Open Access
Precise measurement of CRISPR genome editing outcomes through single-cell DNA sequencing
Molecular Therapy — Methods & Clinical Development·2025· 6 citedOpen Access
Figure S4 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Data from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S1 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S3 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S2 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Provider Support of Parenteral Nutrition Order Writing by Registered Dietitians
Journal of the Academy of Nutrition and Dietetics·2024Open Access
Parenteral Nutrition Order Writing by Registered Dietitians Reduces Bottlenecking of Orders to Pharmacy Staff
Journal of the Academy of Nutrition and Dietetics·2024Open Access
Quantifying allele-specific CRISPR editing activity with CRISPECTOR2.0
Nucleic Acids Research·2024· 6 citedOpen Access
Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
Cancer Immunology Research·2024· 8 cited
Evolution of Gene Therapy for Inborn Errors of Immunity
JAMA Pediatrics·2024· 5 cited
Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells
International Journal of Molecular Sciences·2023· 9 citedOpen Access
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
Molecular Therapy — Nucleic Acids·2023· 8 citedOpen Access
CRISPR-Cas9 engineering of the RAG2 locus via complete coding sequence replacement for therapeutic applications
Nature Communications·2023· 20 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Matthew H. Porteus(10), Zvi Livneh(9), Ortal Iancu(8), Daniel Allen(8), Nechama Kalter(8), Michael A. Rosenberg(7), Yu Nee Lee(7), Raz Somech(7), Rasmus O. Bak(6), Atar Lev(5), Katia Beider(4), Arnon Nagler(4), Anthony Simon(4), Alec B. Wilkens(3), Daniel P. Dever(3), Joab Camarena(3), Noam Diamant(3), Zohar Yakhini(3), Lior Izhar(3), Gali Arad(3)